CSOP Hang Seng Biotech ETF (03174.HK) Rose 2.06% in Morning Trade, Turnover at HKD 3.6262 Million
NewTimeSpace News: As of 10:00 on July 22, CSOP Hang Seng Biotech ETF (03174.HK) advanced 2.06%, with the latest price at HKD 3.462. The ETF opened at HKD 3.388, reached a high of HKD 3.496 and a low of HKD 3.388, with an intraday amplitude of 3.18%. It traded 1,050,600 shares with a turnover of HKD 3.6262 Million and an average price of HKD 3.452. The latest Net Asset Value (NAV) stands at HKD 3.389. Assets Under Management (AUM) at HKD 860 Million, with 254 Million total shares issued and a board lot size of 100 shares.
CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The index covers biotech companies listed in Hong Kong, focusing on pharmaceuticals, biotechnology, medical equipment, and other fields, capturing innovative growth opportunities in the Hong Kong biotech sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP HS Biotech(03174.HK) +2.81%, Hengrui 9M net profit up 20.38%
- Chinese Innovative Drugs Set Record Share of ESMO Late-Breaking Abstracts; CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.81% Intraday
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.55% Intraday as Record 29 Chinese Studies Make ESMO Late-Breaker List
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 1.80% Intraday as Hansoh Signs Roche ADC Deal with US$400 Million Upfront